We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
-15.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$138M
AUM Growth
-$54.6M
Cap. Flow
-$14.6M
Cap. Flow %
-10.54%
Top 10 Hldgs %
60.84%
Holding
122
New
13
Increased
15
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$2.49M
2
ADTN icon
Adtran
ADTN
+$2.33M
3
VIR icon
Vir Biotechnology
VIR
+$2.27M
4
SSYS icon
Stratasys
SSYS
+$1.84M
5
PUBM icon
PubMatic
PUBM
+$1.47M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.18M
2
AFRM icon
Affirm
AFRM
+$2.92M
3
UPST icon
Upstart Holdings
UPST
+$2.87M
4
NUAN
Nuance Communications, Inc.
NUAN
+$2.06M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$1.81M

Sector Composition

Rank Sector Weight
1 Healthcare 81.55%
2 Technology 7%
3 Communication Services 4.59%
4 Consumer Discretionary 2.09%
5 Energy 2.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.14B
$23.6M 17.04%
258,100
-10,100
-4% -$1.08M
ARCT icon
2
Arcturus Therapeutics
ARCT
$178M
$17.7M 12.83%
479,400
+24,100
+5% +$982K
ARWR icon
3
Arrowhead Research
ARWR
$12.2B
$14M 10.09%
210,500
+16,500
+9% +$1.13M
CLSD
4
DELISTED
Clearside Biomedical
CLSD
$6.83M 4.94%
165,567
+1,067
+0.6% +$69.1K
AUPH icon
5
Aurinia Pharmaceuticals
AUPH
$1.95B
$4.31M 3.12%
188,500
+8,500
+5% +$201K
KRYS icon
6
Krystal Biotech
KRYS
$9.64B
$4.13M 2.98%
59,000
+19,000
+48% +$1.11M
IDYA icon
7
IDEAYA Biosciences
IDYA
$3.47B
$4.1M 2.97%
173,500
– –
FUBO icon
8
FuboTV Inc
FUBO
$314M
$3.58M 2.59%
19,208
-1,934
-9% -$544K
NTRA icon
9
Natera
NTRA
$39.3B
$3.03M 2.19%
32,400
+6,500
+25% +$675K
UTHR icon
10
United Therapeutics
UTHR
$22B
$2.92M 2.11%
13,500
+3,000
+29% +$589K
ADTN icon
11
Adtran
ADTN
$641M
$2.63M 1.9%
+115,000
New +$2.33M
META icon
12
Meta Platforms (Facebook)
META
$1.5T
$2.52M 1.82%
+7,500
New +$2.49M
VIR icon
13
Vir Biotechnology
VIR
$1.54B
$2.43M 1.76%
+58,000
New +$2.27M
INMB icon
14
INmune Bio
INMB
$50.5M
$2.35M 1.7%
230,500
-44,500
-16% -$659K
ICAD
15
DELISTED
iCAD Inc
ICAD
$2.33M 1.69%
324,100
+99,600
+44% +$888K
SSYS icon
16
Stratasys
SSYS
$778M
$2.29M 1.66%
93,500
+66,000
+240% +$1.84M
AWH
17
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$1.77M 1.28%
66,667
-8,714
-12% -$331K
AIRS icon
18
AirSculpt Technologies
AIRS
$349M
$1.75M 1.26%
+101,500
New +$1.42M
NVNO
19
enVVeno Medical
NVNO
$7.39M
$1.73M 1.25%
7,500
– –
AFMD
20
DELISTED
Affimed
AFMD
$1.71M 1.23%
30,880
+2,750
+10% +$170K
IKT icon
21
Inhibikase Therapeutics
IKT
$377M
$1.58M 1.14%
179,417
+11,084
+7% +$122K
PUBM icon
22
PubMatic
PUBM
$627M
$1.53M 1.11%
+45,000
New +$1.47M
CVX icon
23
Chevron
CVX
$371B
$1.47M 1.06%
12,500
-3,500
-22% -$398K
GLBE icon
24
Global E Online
GLBE
$6.98B
$1.43M 1.03%
+22,500
New +$1.35M
MYOV
25
DELISTED
Myovant Sciences Ltd.
MYOV
$1.32M 0.96%
85,000
– –
1
2 3 4 5

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, ACT Capital Management held 122 positions worth $138M, down 28% from $193M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

ACT Capital Management withdrew a net $14.6M in Q4 2021, closing 30 positions and reducing 28 holdings. Its most notable exit was Trillium Therapeutics Inc., an estimated $8.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Technology and Communication Services.

Against the trend, ACT Capital Management opened a new position in Meta Platforms (Facebook) worth $2.52M.

  • ACT Capital Management's largest Q4 2021 buy was Meta Platforms (Facebook): 7,500 shares worth $2.52M.
  • ACT Capital Management added most to Stratasys in Q4 2021, an estimated $1.84M increase.
  • ACT Capital Management's biggest Q4 2021 reduction was Upstart Holdings, cutting an estimated $2.87M.
  • ACT Capital Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $8.18M.
  • ACT Capital Management's ten largest holdings make up 61% of its $138M portfolio in Q4 2021.
  • ACT Capital Management opened 13 new positions and closed 30 in Q4 2021.
  • ACT Capital Management's portfolio value fell 28% quarter-over-quarter to $138M.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.